EUCTR2015-001635-21-NO进行中（未招募）不适用
orwegian Pancreatic Cancer Trial - NorPACT-1
orwegian Gastointestinal Cancer Group0 个研究点开始时间: 2015年6月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Resectable pancreatic cancer
- •Performance status 0-2
- •Histologically confirmed diagnosis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Metastatic disease
- •Non-resectable primary pancreatic cancer
研究者
相似试验
进行中（未招募）
1 期
ordic Pancreatic Cancer TrialResectable pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2015-001635-21-DKorwegian Gastointestinal Cancer Group140
进行中（未招募）
1 期
orPACT-1Resectable pancreatic cancerMedDRA version: 20.0Level: LLTClassification code 10007071Term: Cancer of head of pancreasSystem Organ Class: 100000004864EUCTR2015-001635-21-SESwedish studygroup for pancreatic cancer (SSPAC)126
招募中
2 期
PAT-07Borderline resectable pancreatic cancerBorderline resectable, pancreatic cancerD021441JPRN-jRCTs041200028Kodera Yasuhiro50
招募中
2 期
agoya University Pancreatic Tumor Board trial 08ocally advanced pancreatic cancerJPRN-jRCTs041200054Kodera Yasuhiro50
进行中（未招募）
不适用
A trial comparing the current standard treatment (gemcitabine) to the experimental, combined treatments of gemcitabine plus capecitabine.Resectable pancreatic or peri-ampullary cancersMedDRA version: 14.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10034446Term: Periampullary carcinoma resectableSystem Organ Class: 100000004864EUCTR2007-004299-38-GBThe University of Liverpool1,396